التفاصيل البيبلوغرافية
| العنوان: |
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial |
| المؤلفون: |
O'Donnell, Elizabeth, Mo, Clifton, Yee, Andrew J, Nadeem, Omar, Laubach, Jacob, Rosenblatt, Jacalyn, Munshi, Nikhil, Midha, Shonali, Cirstea, Diana, Chrysafi, Pavlina, Horick, Nora, Richardson, Paul G, Raje, Noopur |
| المصدر: |
The Lancet Haematology; June 2024, Vol. 11 Issue: 6 pe415-e424, 10p |
| مستخلص: |
Isatuximab is a CD38 monoclonal antibody approved for relapsed or refractory multiple myeloma. We aimed to evaluate the addition of isatuximab to weekly carfilzomib (K), lenalidomide (R), and dexamethasone (d; Isa-KRd) in transplant-eligible patients with newly diagnosed multiple myeloma and stratified maintenance by cytogenetic risk. |
| قاعدة البيانات: |
Supplemental Index |
